secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001387131-23-007787
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharma acquires two FDA-approved migraine products Zembrace SymTouch and Tosymra for $25M cash plus earn-outs
--------------------------------------------------------------------------------

- Upfront $12M at closing, $3M in Mar 2024, ~$10M for inventory; earn-out royalties based on net sales tiers.
- Acquired products generated ~$23M in 2022 sales (Zembrace $19.6M, Tosymra $3.5M); patent protection to 2036/2031.
- Closing expected June 30, 2023; Upsher-Smith provides transition services for up to 9 months post-close.
- Deal builds commercial infrastructure ahead of potential TNX-102 SL fibromyalgia launch; aligns with TNX-1900 chronic migraine program.
- Managed care contracts covering ~200M patients; products bypass GI tract, useful for migraine with nausea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/tnxp_8k-062323.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-007787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer